Novartis Resubmits Onbrez To FDA; Touts Comparative Trial Against Spiriva
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Novartis AG, looking to position its once-daily Onbrez Breezhaler (indacaterol) to steal market share from the only once-daily bronchodilator approved for chronic obstructive pulmonary disease, Boehringer Ingelheim GMBH/Pfizer Inc.’s Spiriva (tiotropium), released Phase III data from a head-to-head study comparing the two products.
You may also be interested in...
COPD Market Snapshot: Firms Brush Off Near-term Generic Challenges, Focus On Pipelines
Generics are looming for top-selling chronic obstructive pulmonary disease therapies, but Big Pharma continues to see tremendous growth opportunities in the space
Despite European Nod, Novartis Gets FDA "Complete Response" For Indacaterol
FDA requests additional dosing information for the chronic obstructive pulmonary disorder drug, also known as QAB149.
Merck & Co. Remains 'Very Confident' In TIGIT
Despite initial underwhelming competitive data on the cancer target, Merck said it is expanding its investment behind its anti-TIGIT drug vibostolimab. Roche updated investors on its program too.